Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of IMRT with weekly TC versus S-1 in elderly esophageal squamous cell carcinoma
ChiCTR2500095263Phase 3Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jan 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of liposomal paclitaxel, carboplatin and tegafur in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Median survival. Started Jan 2025; status: recruiting.
02
Drugs
liposomal paclitaxelcarboplatintegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500095263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095263.